
Purdue Pharma Files for Bankruptcy Protection
States oppose the company’s plans for a Chapter 11 settlement, which would restructure the company as a trust and cap funding to plaintiffs, Reuters and other news outlets report.
On Sept. 15, 2019, Purdue Pharma LP, manufacturer of the opioid painkiller OxyContin, a form of oxycodone, filed for Chapter 11 bankruptcy protection in White Plains, NY,
Purdue plans to restructure the company as part of the proposed agreement, which would settle suits with 24 states, five territories, more than 2000 cities, as well as other plaintiffs, Reuters reports, noting that the states are opposed to the settlement. Opponents to the settlement want Purdue’s owners to offer more money, Reuters reports.
Under terms of the agreement, the Sacklers would surrender control of the company and offer $4.5 billion in cash including future proceeds from the sale of another asset, Mundipharma, according to Purdue. Purdue Pharma would become a trust that would provide at no or very low cost, tens of millions of doses of drugs that the company developed to counter the effects of opioid addiction and overdoses, Reuters reports. Purdue believes that these drugs would be valued at $4.45 billion during the next 10 years. The Sacklers do not plan to revise their offer, Reuters reports. One
Purdue’s corporate management team has argued that opposing the settlement would lead to longer litigation and higher legal fees, and that it could steer money away from the communities that have been most seriously affected by opioid abuse, Reuters reports.
The restructuring and settlement will determine how much funding communities receive from the company. Both must be approved by a US bankruptcy judge, according to Reuters.
States suing the Sacklers, such as New Jersey,
New York Attorney General Letitia James said that she had uncovered approximately $1 billion in wire transfers between the Sacklers, in particular former board member Mortimer Sackler, and their partners, Reuters reports, as well as financial institutions, including Swiss banks. For more information, see
The transfers, she claimed, suggest that Purdue used shell companies to move money and then hide it in real-estate investments in New York City, according to Reuters. Mortimer Sackler called amassing evidence of these transfers “a cynical attempt … to generate defamatory headlines to try to torpedo a mutually beneficial settlement,” according to Reuters, which notes that Purdue plans to ask the judge to stop active litigation so that it can negotiate a final settlement.
Sources
Purdue Pharma Files For Bankruptcy Protection,
New Jersey Redacted Legal Complaint, https://www.nj.gov/oag/newsreleases19/Sackler-Complaint-Redacted.pdf
Purdue Pharma Files Bankruptcy as Part of a Settlement, https://www.nbcnews.com/news/us-news/purdue-pharma-maker-painkiller-oxycontin-files-bankruptcy-part-settlement-n1054711
Who are the Sacklers? https://www.businessinsider.com/who-are-the-sacklers-wealth-philanthropy-oxycontin-photos-2019-1
New York Attorney General Exposes $1 Billion in Wire Transfers by the Sackler Family, https://ktla.com/2019/09/14/new-york-attorney-general-exposes-1-billion-in-wire-transfers-by-sackler-family/
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.





